GoodRx (NASDAQ:GDRX – Get Free Report) is expected to post its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect GoodRx to post earnings of $0.08 per share and revenue of $193.2310 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.
GoodRx (NASDAQ:GDRX – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. The business had revenue of $194.01 million during the quarter, compared to analysts’ expectations of $185.40 million. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.09 EPS. On average, analysts expect GoodRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
GoodRx Stock Performance
Shares of GDRX stock opened at $3.12 on Wednesday. The company has a market cap of $1.07 billion, a P/E ratio of 52.01, a PEG ratio of 1.41 and a beta of 1.60. The firm has a fifty day moving average price of $2.85 and a 200 day moving average price of $2.52. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.78. GoodRx has a 12 month low of $1.77 and a 12 month high of $5.81.
Analysts Set New Price Targets
View Our Latest Report on GoodRx
Hedge Funds Weigh In On GoodRx
Several hedge funds have recently made changes to their positions in GDRX. Quarry LP acquired a new position in GoodRx during the third quarter worth approximately $33,000. MML Investors Services LLC acquired a new position in GoodRx in the 4th quarter valued at about $36,000. DRW Securities LLC acquired a new position in GoodRx in the 4th quarter valued at about $40,000. Boothbay Fund Management LLC purchased a new stake in shares of GoodRx during the third quarter worth approximately $43,000. Finally, EP Wealth Advisors LLC purchased a new position in GoodRx during the 4th quarter worth $44,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.
About GoodRx
GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.
Recommended Stories
- Five stocks we like better than GoodRx
- Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile
- NVIDIA’s OpenAI Backstop Puts AI Financing Risk in Focus
- UPS Just Gave Investors a Second Chance to Buy
- Welltower at 52-Week Highs—But Analysts Believe There’s More to Come
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.
